Merry Christmas and a Happy New Year 2025 – MS News and Therapy
A Glimpse into the Future of Multiple Sclerosis Treatment
As the year draws to a close, Professor Mathias Mäurer, Chief of Neurology at Würzburg-Mitte Clinic, board member of AMSEL e.V., and a prominent neurology blogger, reflects on the advancements in multiple sclerosis (MS) treatment and offers a glimpse into what the future holds.
While current therapies effectively manage the inflammatory aspect of MS, preventing relapses and symptom betterment, there’s still room for progress in tackling the disease’s progressive nature. This slow, often silent progression can occur from the outset, autonomous of relapses.”Preventing this progression more effectively than current therapies allows is the challenge for the future,” says Mäurer. He believes cell therapies, such as CAR-T cell therapy, could emerge as a game-changer, similar to the revolutionary impact of monoclonal antibodies.
Predicting the future is always challenging, but Mäurer emphasizes the importance of patient education. Germany excels in this area, thanks to resources like www.amsel.de, the German MS Society, and the Competence Network for Multiple Sclerosis (KKNMS).
Recognizing the need to reach a wider audience, Mäurer has made his MS-Docblog accessible in both German and English, ensuring that non-native speakers can benefit from the data.
In this spirit,Professor Mäurer and the entire AMSEL team extend their warmest wishes:
Frohe Weihnachten und ein glückliches Neues Jahr! merry Christmas and a happy New Year!
A Glimpse into the Future of Multiple Sclerosis treatment
NewsDirectory3.com Exclusive Interview
As the year draws to a close, Professor Mathias Mäurer, Chief of Neurology at Würzburg-Mitte Clinic, board member of AMSEL e.V., and a prominent neurology blogger, takes stock of the advancements in multiple sclerosis (MS) treatment and offers a glimpse into what the future holds for this complex disease.
While current therapies effectively manage the inflammatory aspect of MS, preventing relapses and slowing symptom progression, there’s still a critically important challenge: addressing the disease’s progressive nature. This slow, frequently enough silent progression can occur independently of relapses.
“Preventing this progression more effectively than current therapies allows is the challenge for the future,” says Mäurer. He believes cell therapies, such as CAR-T cell therapy, could emerge as a game-changer, mirroring the revolutionary impact of monoclonal antibodies.
Predicting the future is always complex, but Mäurer emphasizes the importance of patient education. Germany excels in this area, thanks to resources like www.amsel.de, the German MS Society, and the Competence Network for Multiple Sclerosis (KKNMS).
Recognizing the need for global accessibility, Mäurer has made his MS-Docblog available in both German and English, ensuring that non-native speakers can benefit from the latest details.
professor Mäurer and the entire AMSEL team extend their warmest wishes:
Frohe Weihnachten und ein glückliches Neues Jahr! Merry Christmas and a happy New Year!